| Literature DB >> 32274655 |
Anne-Tove Brenne1,2, Anne Kari Knudsen3,4, Sunil Xavier Raj5,6, Laila Skjelvan5,6, Jo-Åsmund Lund5,7, Morten Thronæs5,6, Erik Torbjørn Løhre5,6, Liv Ågot Hågensen8, Cinzia Brunelli9, Stein Kaasa3,4,10.
Abstract
INTRODUCTION: Early access to cancer palliative care is recommended. Descriptions of structures and processes of outpatient palliative care clinics operated within smaller hospitals are scarce. This paper presents the development and operation of a fully integrated cancer and palliative care outpatient clinic at a local hospital in a rural region of Mid-Norway offering palliative care concurrent with cancer treatment. A standardized care pathway was applied.Entities:
Keywords: Cancer palliative care; Care delivery model; Early integration; Outpatient clinic; Rural region
Year: 2020 PMID: 32274655 PMCID: PMC7203320 DOI: 10.1007/s40122-020-00163-7
Source DB: PubMed Journal: Pain Ther
Fig. 1Example of SCP aiming at improving coordination and quality of treatment and care across healthcare levels
Fig. 2The Norwegian palliative care model
Fig. 3Major stakeholders of Cancer and Palliative Care Services in the Orkdal region
Milestones and timeline of the development process of the integrated cancer and palliative care outpatient clinic, the descriptive study, and the Orkdal Model Trial
Content of clinical practice of the Integrated Cancer and Palliative Care Services in the Orkdal region
| Clinical practice | |
|---|---|
| Healthcare providers’ approach to care | |
| All healthcare providers | Focus on Functional status, symptom burden, and individual needs Smooth transition between levels Transfer of medical information Availability of healthcare personnel with competence in palliative cancer care 24/7 Available symptom assessment tools Support to carers |
| Fully integrated outpatient clinic for cancer and palliative care | |
| Staff | Oncologists and cancer nurses trained in palliative care |
| Palliative care team | Oncologist, cancer nurse, physiotherapist, occupational therapist, dietician, social worker, and chaplain Weekly meetings to coordinate patients’ services and for educational purposes |
| Consultations | Medical history and physical examination Social and living conditions Assessment of Symptoms using EAPC Basic Dataset [ Performance status using ECOG/WHO PS scale [ Weight and nutritional status Side effects of anti-cancer treatment Need of referral to palliative care team? Need of contact with community care? Discussed with the patient: Treatment intention, treatment plan, side effects, preferences Action plan for follow-up and evaluation Patient receives information (also written) regarding: Medication Ongoing anti-cancer treatment and side effects Resources available for the patient Contact information 24/7 Joint consultation with oncologist and nurse when anti-cancer treatment is stopped Routine consultation with cancer nurse before start of anti-cancer treatment |
| Outpatient follow-up | Adapted to where the patient is in the disease trajectory, symptom burden, needs and if the patient has contact with community care services: Visits at the Integrated Clinic Telephone follow-up from an oncology/palliative care nurse Referral to allied healthcare professionals Ambulatory home visits |
| On-call service | 24-h to Integrated Clinic or ward (local hospital or tertiary hospital) staffed with nurses and physicians trained in cancer and palliative care |
| Carers | Encouraged to accompany the patient Assessment of carer’s needs by use of The Carer Support Needs Assessment Tool (CSNAT) [ Separate carer consultations Follow-up of carers 4–6 weeks after patients’ death |
| Hospital service | |
| Inpatient care | Designated beds for palliative care |
| Inpatient staff | Ward cancer nurses trained in palliative care Ward rounds three times a week routinely and upon request by oncologist trained in palliative care |
| Palliative care team (same team as at the Integrated Clinic) | Weekly meetings to coordinate patients’ services and for educational purposes |
| Palliative care training | Nurses are part of the network of resource nurses in cancer and palliative care Oncologist teaches internal medicine physicians in palliative cancer care four times a year |
| Inpatient follow-up | Coordinated with follow-up from the outpatient clinic |
| Community care | |
| Staff | GP, resource nurses with expertise in cancer and palliative care, home care nurses, nursing home nurses and nurse assistants who have attended educational courses in palliative cancer care |
| Community care access | Contact with community cancer nurses and/or home care is offered repeatedly to patients and carers Contact information is given |
| Communication between hospital and GP or physician at nursing home | Routine (written information) Emphasis on communication of what information the cancer patient and their carers have received from the oncologist Telephone contact when the patient has a high symptom burden |
| Communication between hospital and home care nurses | Routine, if applicable |
| Follow-up | Dependent on preferences, needs, symptom burden, geography and where the patient is in the disease trajectory: Contact with GP Contact with resource nurses in cancer and palliative care Home nursing care |
Fig. 4Inpatient and outpatient hospital care and community care located on the same floor at Orkdal Hospital
Characteristics of cancer patients attending the integrated clinic (N = 88)
| Gender | |
| Male | 43 (48.9%) |
| Female | 45 (51.1%) |
| Treatment intention | |
| Curative | 36 (40.9%) |
| Non-curative | 52 (59.1%) |
| Age (mean, standard deviation) | 65.6 (12.0) |
| Median months (Q1–Q3)a from cancer diagnosis to first visit | 7.2 (1.5–66.0) |
| Cancer diagnosis | |
| Digestive organs | 20 (22.7%) |
| Male genital organs | 18 (20.5%) |
| Breast | 22 (25.0%) |
| Lymphoid, haematopoietic and related tissue | 9 (10.2%) |
| Female genital organs | 8 (9.1%) |
| Otherb | 11 (12.5%) |
| Disease stage | |
| Metastatic | 46 (52.3%) |
| Locally advanced | 20 (22.7%) |
| Localised | 22 (25.0%) |
| Karnofsky performance statusc | |
| 90–100% | 48 (54.5%) |
| 70–80% | 34 (38.6%) |
| 50–60% | 5 (5.7%) |
| Worse than 50% | 0 |
| Missing | 1 |
| Ongoing anti-cancer treatment at inclusion | |
| Yes | 69 (78.4%) |
| No | 19 (21.6%) |
| Type of ongoing anti-cancer treatment | |
| Chemotherapy (including targeted therapy) | 43 (48.9%) |
| Radiotherapy | 1 (1.1%) |
| Hormone therapy | 24 (27.3%) |
| Other | 12 (13.6%) |
| Ongoing pain treatment at inclusion | |
| Yes | 23 (26.1%) |
| No | 65 (73.9%) |
| Type of ongoing pain treatment | |
| Paracetamol/NSAIDd | 11 (12.5%) |
| Weak opioids (e.g. codein) | 2 (2.3%) |
| Strong opioids (e.g. morphine) | 10 (11.4%) |
| Other | 1 (1.1%) |
| Median months (Q1–Q3) of study follow-upe | 41.5 (19.4–50.0) |
| Survival status by Oct 31, 2017 | |
| Alive | 39 (44.3%) |
| Dead | 48 (54.5%) |
| Lost to follow-up | 1 (1.1%) |
| Medical anti-cancer treatmentf last 90 days of life | 22 (45.8%) |
| Medical anti-cancer treatmentf last 30 days of life | 6 (12.5%) |
| Place of death | |
| Hospital | 21 (43.7%) |
| Nursing home | 15 (31.3%) |
| Home | 12 (25.0%) |
a(Q1–Q3), interquartile range
bOther cancer diagnoses included respiratory and intrathoracic organs, urinary tract, central nervous system, ill-defined, secondary and unspecified sites, and thyroid and other endocrine glands
cKarnofsky performance status was rated from 0 (dead) to 100 (no functional impairment)
dNSAID, nonsteroidal anti-inflammatory drugs
eFrom first visit at the Integrated Clinic to Oct 31, 2017 or death
fDoes not include hormone therapy
Symptom intensities reported by patients attending the Integrated Clinic (N = 88)
| Symptoma | Median (Q1–Q3)b | Rating ≥ 4c |
|---|---|---|
| Pain | 0 (0–3) | 19 (21.6) |
| Tiredness/drowsiness | 3 (0–4) | 30 (34.1) |
| Insomnia | 0.5 (0–3) | 19 (21.6) |
| Nausea | 0 (0–1) | 8 (9.1) |
| Vomiting | 0 (0–0) | 1 (1.1) |
| Constipation | 0 (0–0) | 6 (6.8) |
| Diarrhea | 0 (0–0) | 4 (4.5) |
| Dry mouth | 1 (0–3) | 20 (22.7) |
| Lack of appetite | 0 (0–2) | 15 (17.0) |
| Shortness of breath | 0 (0–3) | 19 (12.6) |
| Depression | 0 (0–1) | 12 (13.6) |
| Anxiety | 0 (0–1) | 10 (11.4) |
| Well-being | 2 (0–4) | 26 (29.5) |
| At least one symptom score NRS ≥ 4c | 54 (61.4) |
aSymptom intensity was rated from 0 (the best situation) to 10 (the worst situation)
b(Q1–Q3), interquartile range
cSymptom intensity score numerical rating scale (NRS) ≥ 4 was defined as clinically significant
|
|
| Access to palliative care early in the cancer disease trajectory is recommended. |
| Description of delivery models of integrated cancer and palliative care within smaller hospitals and integrated with community care in rural districts is lacking. |
| This publication presents the development and operation of a fully integrated decentralized cancer- and palliative care program at an outpatient clinic at a local hospital in a rural region of Mid-Norway. |
|
|
| Cancer and palliative care were at the outpatient clinic provided by one team of healthcare professionals trained in both fields collaborating closely with the other departments at the hospital, the affiliated tertiary hospital and health and care services in the surrounding communities. |
| A high proportion of cancer patients attending the integrated outpatient clinic was treated with non-curative intention and had low symptom burden, making it possible to offer palliative care services at an early stage of the cancer disease before symptoms became severe. |